Buspirone-Induced Jitteriness Syndrome
Jitteriness syndrome from buspirone presents with increased anxiety, agitation, restlessness, pressured speech, racing thoughts, and motor restlessness (akathisia), and these symptoms typically resolve completely after discontinuing the medication. 1, 2
Clinical Presentation
The syndrome manifests as a constellation of symptoms including:
- Neuropsychiatric symptoms: Nervousness, excitement, increased anxiety levels, agitation, and racing thoughts 1, 2
- Motor symptoms: Restlessness, akathisia (motor restlessness), tremor, and involuntary movements 1
- Speech changes: Pressured speech 2
- Associated symptoms: Insomnia, dizziness, and lightheadedness 1
The FDA label specifically describes "a syndrome of restlessness, appearing shortly after initiation of treatment" that has been reported in a small fraction of buspirone-treated patients 1. This may be explained by buspirone's ability to increase central noradrenergic activity or represent dopaminergic effects (akathisia) 1.
Time Course and Resolution
Yes, these symptoms disappear with time—specifically, they completely resolve after buspirone discontinuation. 2 The research evidence demonstrates that all four patients who developed jitteriness syndrome experienced complete resolution of symptoms once buspirone was stopped 2.
The syndrome typically appears:
- Shortly after treatment initiation (within the first 2 weeks in most cases) 1, 3
- With dose increases 1
- The median time to onset for adverse events is 10 days 4
Important Clinical Considerations
Distinguish jitteriness from serotonin syndrome: While jitteriness presents with restlessness and anxiety, serotonin syndrome is a medical emergency characterized by mental status changes (confusion, agitation, hallucinations), neuromuscular hyperactivity (tremor, rigidity, myoclonus, hyperreflexia), and autonomic instability (tachycardia, hypertension, hyperthermia, diaphoresis) 1. Serotonin syndrome requires immediate discontinuation of all serotonergic agents and hospital-based supportive care 1.
Risk factors for jitteriness: Patients with panic disorder may have unusual adrenergic sensitivity that predisposes them to this syndrome 2. Higher antidepressant doses are associated with increased jitteriness risk (OR 2.68) 3, though this data comes from other antidepressants.
Management approach: If jitteriness develops, discontinue buspirone—symptoms will resolve completely 2. The FDA label notes that approximately 10% of patients discontinued buspirone in premarketing trials due to adverse events, with CNS disturbances (primarily dizziness, insomnia, nervousness, drowsiness) being the most common reason at 3.4% 1.